相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
在临床接触中修补减肥药物:一项民族学研究
Sissel Due Jensen1, Annelli Sandbæk2, Jens Meldgaard Bruun3
1Department of Public Health, Aarhus University, Aarhus, Denmark; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Social science & medicine (1982)
|September 16, 2025
概括
患者使用塞马格卢提德减肥表现出强烈的承诺,尽管副作用和日常干扰. 医疗保健专业人员管理期望,并导航围绕肥胖治疗的道德考虑.
科学领域:
- 医学社会学 医学社会学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 作为GLP-1受体激动剂的塞马格卢提德越来越多地用于减肥,达到高达15%的减肥.
- 它的快速采用交叉制药利益,公共卫生和文化身体形象理想,需要检查其影响.
研究的目的:
- 探索患者和医疗保健专业人员在临床环境中使用减肥药物的导航.
- 分析如何管理GLP-1受体激动剂的时间,剂量和副作用在丹麦的一般实践.
主要方法:
- 在三个丹麦一般实践中进行了为期三个月的民族学实地调查.
- 临床经验分析,重点关注GLP-1受体激动剂使用的患者与医疗服务提供者的相互作用.
主要成果:
- 患者表现出显著的奉献精神,获得和继续减肥药物,即使生活中断.
- 医疗保健专业人员调解患者对快速减肥的期望,并解决治疗的道德方面,包括动机和副作用.
结论:
- 患者对GLP-1受体激动剂的承诺凸显了肥胖耻辱,恐惧和焦虑的复杂问题.
- 临床经验显示,关于适当的减肥方法和可接受的治疗参数,正在进行谈判.
相关概念视频
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
The Placebo Effect
6.8K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.8K
Dosage Regimens: Designs and Approaches
266
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
266

